606 related articles for article (PubMed ID: 24279716)
21. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
[TBL] [Abstract][Full Text] [Related]
22. GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease.
Schneider JS; Aras R; Williams CK; Koprich JB; Brotchie JM; Singh V
Sci Rep; 2019 Jun; 9(1):8362. PubMed ID: 31182727
[TBL] [Abstract][Full Text] [Related]
23. Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.
Thakur P; Breger LS; Lundblad M; Wan OW; Mattsson B; Luk KC; Lee VMY; Trojanowski JQ; Björklund A
Proc Natl Acad Sci U S A; 2017 Sep; 114(39):E8284-E8293. PubMed ID: 28900002
[TBL] [Abstract][Full Text] [Related]
24. Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.
Alarcón-Arís D; Recasens A; Galofré M; Carballo-Carbajal I; Zacchi N; Ruiz-Bronchal E; Pavia-Collado R; Chica R; Ferrés-Coy A; Santos M; Revilla R; Montefeltro A; Fariñas I; Artigas F; Vila M; Bortolozzi A
Mol Ther; 2018 Feb; 26(2):550-567. PubMed ID: 29273501
[TBL] [Abstract][Full Text] [Related]
25. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
26. Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease.
Davies SE; Hallett PJ; Moens T; Smith G; Mangano E; Kim HT; Goldberg AL; Liu JL; Isacson O; Tofaris GK
Neurobiol Dis; 2014 Apr; 64(100):79-87. PubMed ID: 24388974
[TBL] [Abstract][Full Text] [Related]
27. Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson's disease.
Musacchio T; Yin J; Kremer F; Koprich JB; Brotchie JM; Volkmann J; Ip CW
Behav Brain Res; 2022 Aug; 432():113968. PubMed ID: 35738338
[TBL] [Abstract][Full Text] [Related]
28. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
29. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
30. Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.
Naughton C; O'Toole D; Kirik D; Dowd E
Behav Brain Res; 2017 Jan; 316():160-168. PubMed ID: 27585560
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M
J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446
[TBL] [Abstract][Full Text] [Related]
32. Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease.
Phan JA; Stokholm K; Zareba-Paslawska J; Jakobsen S; Vang K; Gjedde A; Landau AM; Romero-Ramos M
Sci Rep; 2017 Jul; 7(1):6363. PubMed ID: 28743955
[TBL] [Abstract][Full Text] [Related]
33. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
34. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
[TBL] [Abstract][Full Text] [Related]
35. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ
Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of α-Synuclein Protein Levels by an Intracellular Single-Chain Antibody.
Chen YH; Yu SJ; Wu KJ; Wang YS; Tsai HM; Liao LW; Chen S; Hsieh W; Chen H; Hsu SC; Chen ML; Hoffer BJ; Wang Y
J Parkinsons Dis; 2020; 10(2):573-590. PubMed ID: 32176654
[TBL] [Abstract][Full Text] [Related]
37. Ciita Regulates Local and Systemic Immune Responses in a Combined rAAV-α-synuclein and Preformed Fibril-Induced Rat Model for Parkinson's Disease.
Fredlund F; Jimenez-Ferrer I; Grabert K; Belfiori LF; Luk K; Swanberg M
J Parkinsons Dis; 2024; 14(4):693-711. PubMed ID: 38728204
[TBL] [Abstract][Full Text] [Related]
38. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
Caudal D; Alvarsson A; Björklund A; Svenningsson P
Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
[TBL] [Abstract][Full Text] [Related]
39. Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein.
Elgueta D; Chovar O; Ugalde V; Sánchez-Guajardo V; Catenaccio A; Court F; Pacheco R
J Vis Exp; 2022 Jul; (185):. PubMed ID: 35969046
[TBL] [Abstract][Full Text] [Related]
40. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.
Chung CY; Koprich JB; Siddiqi H; Isacson O
J Neurosci; 2009 Mar; 29(11):3365-73. PubMed ID: 19295143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
